ETHE1

Across TCGA pan-cancer cohorts, ETHE1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ETHE1 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ETHE1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ETHE1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where ETHE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.611	0.882	<.001	53	view →
PDAC	OS	Tertile	All	0.582	0.396	.006	42	view →
CCRCC	DFS	Median	III,IV	0.384	0.794	.001	24	view →
COAD	DFS	Median	All	1.000	0.885	.018	18	view →
HNSC	DFS	Tertile	All	1.000	0.259	.040	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ETHE1–LUAD (OS)

Open the LUAD breakdown →